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ABSTRACT

Pancreatic cancer is an extremely aggressive cancer with a five-year survival rate of less
than 6%, largely due to the lack of early detection and effective treatment options. A better
understanding of the mechanisms leading to malignant transformation is necessary to improve
patient outcomes. One known contributor to tumor aggression is the cholecystokinin 2 receptor
(CCK2R), a G-protein coupled receptor that binds the gastrointestinal hormones CCK and gastrin.
A constitutively-active form of the receptor, the intron 4 splice variant (CCK2i4svR), has also been
observed in cancer cells. To facilitate studies of CCK2i4svR, a monoclonal antibody specific to an
insertion in its sequence was previously generated, characterized, and cited in a 2012 study.
Currently, a monoclonal antibody which binds an extracellular site common to all forms of CCK2R
is also being developed, as there is no such antibody commercially available. Two anti-CCK2R
candidates have achieved clear immunofluorescent (IF) staining with minimal background
fluorescence in HEK293 cells transiently transfected with the receptor. Each produced primarily
membranous staining patterns, co-localizing with a commercial polyclonal antibody. Detection by
IF and immunohistochemistry (IHC) in cell lines and tumor sections expressing lower levels of
receptor has been inconclusive to date; positive controls have not yet been verified. Once
confirmed for IF, IHC, and Western Blotting, anti-CCK2R will be used to quantify receptor
expression in pancreatic, prostate, and colon cancer cell lines and patient tumor samples. This
information will be utilized in studies targeting CCK2R for diagnosis and drug delivery.

INTRODUCTION

Relevance of Studying Pancreatic Cancer
Pancreatic cancer is an extremely aggressive cancer, leading to about 227,000 deaths per
year worldwide (Vincent et al. 2011). This ranks it as the fourth most deadly cancer, accounting
for 7% of all cancer-caused deaths. The number of people being diagnosed with and dying from
pancreatic cancer has been slowly rising over the past ten years, while the trends for other major
cancers such as lung, colorectal, breast, and prostate have been falling (American Cancer Society
2013). This is partially because the mechanism of pancreatic cancer development is poorly
understood compared to most other cancers.
Sadly, patients diagnosed with pancreatic cancer are typically expected to live only
months. There are several reasons for this poor prognosis. First, because of the lack of available
screening methods and absence of specific symptoms early on, the cancer is often not identified
until it has already metastasized to distant sites in the body. Because diagnosis usually occurs at
the later stages of disease progression, only 26% of patients survive the first year after diagnosis,
and only 6% survive five years (ACS 2013). Second, the disease itself – not including the side
effects of harsh treatment – is quite harmful to the individual as it progresses, leading to weight
loss, muscle atrophy, fatigue, weakness, breathlessness, and significant loss of appetite (Li et al.
2004), along with other effects when the cancer spreads to other organs. Finally, few treatments
can effectively combat the disease. The only hope of a cure is surgical removal of the tumor,
which is only possible in the few patients who are diagnosed prior to metastasis.
In order to improve pancreatic cancer outcomes by providing improved screening and
treatment options, a better understanding of the disease must be achieved through additional
research and funding.

The Role of Gastrin and CCK in Pancreatic Cancer
One area of pancreatic cancer research focuses on the malfunctioning of gastrointestinal
(GI) hormones and receptors that normally regulate digestion. A growing body of evidence has
brought greater attention to the field in recent years. Multiple in vitro and in vivo studies have
demonstrated that abnormal expression of the GI hormones gastrin and cholecystokinin (CCK)
and their receptors contributes to the neoplastic tissue growth. These mechanisms are being
studied with the potential of developing therapies that target these pathways.
Adult pancreatic cells do not typically express gastrin and CCK themselves; they receive
the hormones from endocrine cells in the stomach and duodenum. The fetal pancreas does
express higher amounts of gastrin, often in the unprocessed form, but hormones in the adult
pancreas are present at very low levels, if at all (Bardram 1990).
Neoplastic tissues, however, begin to produce and respond to gastrin and CCK in an
autocrine signaling pathway. Multiple studies have shown that cancer cells express significant
levels of endogenous CCK and gastrin. In 1996, Smith et al. found gastrin expression in both
human pancreatic cell lines and fresh tumors. The expression of CCK was less easily detected,
but in 2010 Matters et al. confirmed low levels of endogenous CCK.
Gastrin and CCK have both been shown to play a contributory role in pancreatic cancer:
increased levels of the hormones speed neoplastic growth. In 1991, Smith et al. observed
increased tumor growth in six cell lines in the presence of exogenous CCK. The group later
demonstrated that exogenous gastrin also stimulated the growth of cancer cells grown in vitro
and tumors grown in mice (1995).

The Gastrin/CCK2 Receptor and the Intron 4 Splice Variant
Pancreatic cancer tissue displays the unique tendency to overexpress both its growthpromoting ligands and the ligands’ receptors. CCK and gastrin are very similar in structure and
bind the same family of G-protein coupled receptors (GPCRs), hydrophobic membrane proteins
characterized by seven transmembrane domains. Two receptors have been characterized:
CCK1R and CCK2R. While CCK2R has been associated with pancreatic cancer, the effects of
CCK1R in cancer have not been demonstrated. Both the upregulation and downregulation of
CCK2R have been shown to significantly affect neoplastic behavior. Smith et al. (1995)
demonstrated that blocking CCK2R with an antagonist suppressed cancer cell growth both in
vitro and in vivo. Additionally, Clerc et al. (2002) showed that transgenic mice overexpressing
CCK2R had increased pancreatic weights and increased risk of developing malignant tumors.
In addition to the expression of normal CCK2R, changes in splicing can also contribute
to pancreatic cancer. Multiple splice variants of CCK2R have been observed in pancreatic
neoplasms (Ryberg et al. 2011) often characterized by either increased or decreased signaling.
One splice variant of particular interest to this laboratory is CCK2i4svR, the CCK2 intron 4 splice
variant receptor. This receptor isoform was identified in human pancreatic cancer cells by Smith
et al. in 2002. CCK2i4svR retains the fourth intron in the DNA sequence of the receptor, resulting
in a perfect 69 amino acid insertion in the third intracellular loop. This alteration causes in
constitutive activation of the receptor even when CCK and gastrin are not present (Hellmich
2000). CCK2i4svR has only been detected in neoplastic tissue, never normal tissue. Not all tumors
express this mutant receptor; Ryberg et al. (2011) found CCK2i4svR expression in only 1 out of
17 tumor biopsies.

Using Antibodies to Detect CCK2R and CCK2i4svR
While studying the hormones and receptors involved in pancreatic cancer, it is useful to
have the ability to detect receptor expression. Particularly, it is essential to confirm the
expression of the protein itself, not just mRNA. This is especially important when studying
splice variants, because it is difficult in qRT-PCR to differentiate genomic DNA from cDNA that
retains an intron.
Antibodies are an attractive option for receptor detection. Monoclonal antibodies, in
particular, are isolated from clones of a single antibody-producing cell and recognize a single
epitope on the protein of interest. By contrast, polyclonal antibodies consist of sera containing a
mixture of antibody-producing cells and therefore recognize multiple epitopes of the target.
Currently, there is no commercially-available monoclonal antibody against human CCK2R. This
laboratory is in the process of developing and characterizing monoclonal antibodies against both
CCK2R and CCK2i4svR as tools for studying the receptors and for potential immunotherapy
applications. Two anti-CCK2R monoclonal antibodies (7B8.8 and 9A4.10) bind to an
extracellular domain common to all forms of the receptor, whereas an anti-CCK2i4svR antibody
(28H8) binds the misspliced intracellular loop unique to CCK2i4svR. These antibodies were
demonstrated to detect the appropriate receptors (both CCK2R and CCK2i4svR, or CCK2i4svR
alone) by immunofluorescence when expressed in transiently transfected human embryonic
kidney (HEK) 293FT cells (Evan Shirey 2014, unpublished). The antibodies achieved good
specificity compared to a background of untransfected cells not expressing the receptor.
However, preliminary studies indicated that, when all antibodies were tested against
CCK2i4svR, 7B8.8 and 9A4.10 produced mainly polarized perinuclear staining patterns similar to
a commercial polyclonal anti-CCK2R antibody, whereas 28H8 produced both polarized

perinuclear and membranous staining (Figure 1). The reason for these observed differential
staining patterns was not known, although it was hypothesized that 28H8 detected a different
subpopulation of CCK2i4svR proteins than was detected by the other three antibodies.
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Figure 1: In preliminary studies,
7B8.8 and 9A4.10 produced
polarized perinuclear staining,
whereas 28H8 produced both
membranous and polarized
perinuclear staining. (A) Abcam
77077 anti-CCK2R polyclonal
antibody, (B) 28H8 anti-CCK2i4svR
monoclonal antibody, (C) 7B8.8 antiCCK2R monoclonal antibody, (D)
9A4.10 anti-CCK2R monoclonal
antibody. All antibodies were tested
on 293FT cells transiently transfected
with CCK2i4svR. (Figure adapted
from Evan Shirey 2014, unpublished).

Additionally, other preliminary results showed that 28H8 anti-CCK2i4svR antibody and
the two anti-CCK2R candidates (9A4.10 and 7B8.8) could not detect the mutated receptor by
immunofluorescence in stably-transfected Panc02 cells expressing the receptor at lower levels
despite confirmation by qRT-PCR (Evan Shirey 2014, unpublished). However, 28H8 had
demonstrated effectiveness in detecting CCK2i4svR in human tumor sections by
immunohistochemistry (Smith et al. 2012). Therefore, the inability of 28H8, 9A4.10, and 7B8.8
to detect the receptor in these Panc02 lines by immunofluorescence was hypothesized to result
from one of the following issues: the receptor has low stability or a low copy number in the cell
lines (potentially due to the effects of growing in vitro rather than in vivo); the
immunofluorescence technique does not achieve the necessary sensitivity compared to

immunohistochemistry; the resolution of the microscope in use was limited; or the fixation
protocol in use did not effectively preserve membrane structure.

Research Aims
The first goal of this research was to further investigate the previously-observed
differential staining patterns by testing new high-titer stocks of 7B8.8 and 9A4.10 and by using a
double-labeling experiment to compare the localization of the antibodies. Unfortunately, 9A4.10,
7B8.8, and 28H8 are all mouse antibodies and therefore cannot be distinguished with different
fluorescence-labeled secondary antibodies (to study them together, fluorescent labeling would
have to be applied directly to the primary antibodies). For this research, each was instead
individually tested pairwise with the goat-derived polyclonal antibody, Abcam 77077 (Table 1).
A second goal of this research was to again attempt to detect CCK2i4svR in stably
transfected Panc02 cells, for two related purposes: first, to determine whether 28H8, 9A4.10, and
7B8.8 are able to detect the receptor expressed at physiological levels by immunofluorescence
(IF) and immunohistochemistry (IHC); and second, to confirm the expression of CCK2i4svR
protein (in addition to mRNA) in this mouse model to validate it for future studies.

Table 1. Antibodies to be compared by double-labeling cells expressing CCK2i4svR.
Target

Antibody Source

Secondary Antibody
Source

CCK2R, all forms

Goat

Donkey

28H8 (monoclonal)

CCK2i4svR

Mouse

Rabbit

9A4.10 and 7B8.8
(monoclonal)

CCK2R, all forms

Mouse

Rabbit

Name of Antibody
Abcam 77077
(polyclonal)

MATERIALS AND METHODS

Transfection of 293FT Cells
HEK293FT cells were cultured in DMEM with 10% fetal bovine serum (FBS) in a 5%
CO2 incubator at 37°C. Lipofectamine 2000 transfection reagent (Invitrogen) was used to
transfect cells with a pCAGEN.neo plasmid encoding CCK2i4svR with mutated splice sites to
ensure intron 4 retention. The following day, both transfected and untransfected cells were
divided among coverslips prepared with poly-D-lysine. After another 24-hour incubation, the
cells were rinsed with phosphate buffered saline (PBS) and frozen in absolute methanol at -20°C.

Antibody Staining and Immunofluorescence
Cells were fixed in acetone at -20°C for 20 minutes, followed by three washes with PBS.
Next, cells were permeabilized in 0.2% Triton X100 in PBS for one hour then blocked in 0.1%
Triton X100 and 5% FBS in PBS for another hour at room temperature. Incubation with primary
antibodies (28H8, 9A4.10, 7B8.8 mouse antibodies and/or Abcam 77077 goat polyclonal
antibody) at various dilutions in 0.05% Triton X100 and 5% FBS in PBS was performed
overnight in the dark at 4°C. After three PBS washes, cells were incubated with secondary
antibodies (Alexa Fluor 488 rabbit anti-mouse and/or Alexa Fluor 594 donkey anti-goat;
Molecular Probes) diluted 1:3000 in 0.05% Triton X100 and 1% FBS in PBS for one hour in the
dark at 4°C. Cells were again washed three times before counterstaining the nuclei with Hoescht
33342 stain at 1 μg/mL for 10 minutes. Coverslips were mounted on glass slides with Aqua-Poly
Mount or Prolong Gold Anti-Fade (for confocal microscopy). Slides were viewed with a Nikon
E600 Fluorescence Microscope equipped with G-2E/C, B-2E/C and UV-2A filter sets.

Photomicrographs were obtained with either a Photometrics CoolSnap CCD camera and
MetaMorph imaging software or a Leica DFC450 C camera and LAS imaging software.

Immunohistochemistry
After paraffin embedding and sectioning, slides were deparaffinized through a series of
xylene and ethanol washes. High-temperature unmasking was performed for one minute in a
pressure cooker with a citrate buffer (10 mM, 0.05% Tween, pH 6.0). Sections were then
incubated in 3% H2O2 for one hour and blocked for one hour in 2.5% FBS in PBS. Avidin and
biotin blocking (Vector Laboratories #SP-2001) was performed according to manufacturer’s
instructions. A mouse-on-mouse kit (Vector Laboratories #BMK-2202) was then used, with a
one hour primary antibody incubation. Sections were then stained (VECTASTAIN Elite ABC
Kit; Vector Laboratories #PK-6100) and developed (ImmPACT DAB chromagen solution,
Vector Laboratories #SK-4105). Finally, sections were counterstained with hematoxylin,
dehydrated, and mounted with Histomount Mounting Solution. Slides were imaged with a Leica
DFC450 C camera and LAS imaging software.

RESULTS
Aim 1: Compare staining patterns produced by 9A4.10 and 7B8.8 with 28H8.
Before double-labeling was attempted, each monoclonal antibody was tested individually
at various concentrations to optimize the quality of staining relative to background. 293FT cells
were transiently transfected with CCK2i4svR, divided onto coverslips, and stained with 9A4.10,
7B8.8, 28H8, and a commercial polyclonal anti-CCK2R antibody (Abcam 77077). Recently
produced high-titer stocks (10,000-40,000 titer) of 9A4.10 and 7B8.8 were used. At higher
concentrations, both polarized perinuclear and membranous staining were observed with all
antibodies (Figure 2). Many of the cells that appeared to have mainly polarized perinuclear or
9A4.10 anti-CCK2R

7B8.8 anti-CCK2R

28H8 anti-CCK2i4svR

Polyclonal anti-CCK2R

Figure 2. All antibodies produced both membranous and polarized
perinuclear staining. 293FT cells from a single transfection with CCK2i4svR
were stained with 9A4.10 (1:1000), 7B8.8 (1:1000), 28H8 (1:2000), and Abcam
77077 (1:1000). High titer stocks of 9A4.10 and 7B8.8 produced brighter
staining than the previously used stocks: some polarized perinuclear and
cytoplasmic staining was visible, but many transfected cells also displayed a
fainter membranous stain.

cytoplasmic staining patterns fluoresced much more brightly than membranous cells and
appeared less adherent when viewed by bright-field microscopy (Figure 3).
To determine whether staining patterns produced by the monoclonal antibodies differed,
each monoclonal antibody was used pairwise with Abcam 77077 to double-label 293FT cells
expressing CCK2i4svR. Each monoclonal antibody colocalized with 77077 (Figure 4). Several
control slides were also prepared. A pool of both secondary antibodies was tested without
primary antibodies to ensure that minimal background staining was produced. The pool of
secondaries was also tested with each primary antibody individually to ensure that secondary
antibod ies were not binding to unexpected targets.
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Figure 3. Polarized perinuclear staining was most often observed in unhealthy cells.
The majority of cells exhibiting polarized perinuclear or cytoplasmic staining patterns
lacked membranous projections, indicating that they did not adhere well to the glass
substrate. One example is highlighted by an arrowhead in (A) fluorescence, (B)
brightfield, and (C) overlay images. This suggests that high-expressing cells may have an
unhealthy phenotype and sequester receptor in the endoplasmic reticulum and other
organelles.

Single-labeled cells
(controls)

Dual-labeled cells
9A4.10 anti-CCK2R
Polyclonal anti-CCK2R

A

9A4.10 anti-CCK2R

E

7B8.8 anti-CCK2R
Polyclonal anti-CCK2R

B

28H8 anti-CCK2i4svR
Polyclonal anti-CCK2R

C

Secondary Antibodies Only

D

7B8.8 anti-CCK2R

F

28H8 anti-CCK2i4svR

G

Polyclonal anti-CCK2R

H

Figure 4. 9A4.10, 7B8.8, and
28H8 each colocalized with the
commercial polyclonal antiCCK2R antibody. 293FT cells
expressing CCK2i4svR were duallabeled with Abcam 77077 goat
antibody (1:1000) antibody and
each mouse monoclonal antibody
individually (1:5000) (panels A-C).
The cells were visualized with a
mixture of green anti-mouse and
red anti-goat secondary antibodies;
yellow fluorescence denotes areas
of red/green colocalization. To
ensure that secondary antibodies
were not binding to unexpected
targets, each primary antibody was
also tested with both secondaries
(panels E-H). With no primary
antibody present, the red secondary
antibody produced slightly more
nonspecific background staining
than the green (panel D).

The intensity of the stain produced by the two anti-CCK2R monoclonal antibody
candidates was then compared to that of 28H8 anti-CCK2i4svR. Antibody concentrations were
adjusted to similar levels (40,000 titer used at a dilution of 1:5000). Although membranous
staining was visible with both the anti-CCK2R candidates and 28H8, staining produced by 28H8
was brighter (Figure 5). Subsequently, 9A4.10 and 7B8.8 were isotyped to determine if the
staining difference was due to the secondary antibody having higher affinity for one primary
over the other. However, both anti-CCK2R candidates were found to be of the same isotype as
28H8 (Figure 6).

Anti-CCK2R:
Candidate 9A4.10

Anti-CCK2R:
Candidate 7B8.8

Anti-CCK2i4svR: 28H8

7B8.8

9A4.10

Figure 5. 28H8 stains more brightly than 9A4.10 and 7B8.8. Primary antibody concentrations were
adjusted to similar levels (1:5000). Anti-CCK2i4svR produced the brightest staining, allowing best
visualization of the receptor at the membrane.

Figure 6. 9A4.10 and 7B8.8 are of the
same isotype as 28H8. Both antiCCK2R monoclonal candidates were
isotyped with a Pierce Rapid Isotyping
Kit and found to be of IgG1 isotype with
a kappa light chain. This is identical to
the isotype of anti-CCK2i4svR (Smith et
al. 2012), so higher affinity of the
secondary antibody for anti-CCK2i4svR
cannot explain the differences in
staining brightness.

Aim 2: Detect receptor expression by IF or IHC in cell lines stably expressing the receptor.
In previous experiments, no receptor expression was detectable in Panc02 mouse
pancreatic cancer cells that had been stably transfected with CCK2R or CCK2i4svR despite
confirmation of mRNA expression. In a pilot experiment, this previous finding was reassessed
by staining Panc02-CCK2i4svR cells with a new high-titer stock of 7B8.8 (1:500) along with
Abcam 77077 (1:1000) as a positive control. No difference was observed between control cells
(Panc02 cells transfected with an empty vector) and Panc02-CCK2i4svR (Figure 7). This outcome
agreed with previous results; however, the interpretation of this pilot experiment is limited
because no positive control cell line, such as transiently-transfected HEK293FT cells, was
employed, and 28H8 was not tested in parallel to reproduce the previous work.

Figure 7. No staining
was observed in
Panc02-CCK2i4svR
cells. Panc02 cells
were transiently
transfected with
CCK2i4svR and stained
with 7B8.8 antiCCK2R or Abcam
77077.

As previously mentioned, the inability to detect lower levels of receptor expression by IF
was thought to result from one of the following hypotheses: the resolution of the microscope in
use was limited; the fixation protocol did not effectively preserve membrane structure; the
receptor has low stability or a low copy number in the cell lines (potentially due to the

limitations of two-dimensional growth in vitro); or the immunofluorescence technique does not
achieve the necessary sensitivity compared to immunohistochemistry.
To address the first hypothesis, an expanded experiment was conducted using confocal
microscopy. Additionally, both Panc02 and PANC-1 (human pancreatic cancer cells) stably
transfected with CCK2i4svR were tested alongside a positive control, transiently-transfected
293FT cells. Unfortunately, the 28H8 stock used for this experiment was subsequently
determined to have no titer, so the 28H8 staining could not be analyzed. However, cells stained
with 7B8.8 (1:1000) were imaged by confocal microscopy (Figure 8). Staining with 7B8.8 was
clearly visible in transiently-transfected 293FT cells but not in the stably-transfected cell lines.
Wild-type Panc02 cells were expected to be a negative control in this experiment as 7B8.8 was
designed to stain only human CCK2R without cross-staining mouse CCK2R, and furthermore,
murine CCK2R mRNA is undetectable in Panc02 cells by qRT-PCR (Matters et al. 2014). Yet,
the other three stably-transfected cell lines showed similar levels of background staining to this
negative control.
Due to time constraints, slides stained with Abcam 77077 were not imaged with the
confocal microscope; however, results obtained with 77077 using the compound microscope
were similar to those obtained with 7B8.8: no staining was evident except in the transientlytransfected 293FT cells.

Figure 8. No immunofluorescent staining was observed in Panc02 (mouse) or
PANC-1 (human) pancreatic cancer cell lines stably expressing CCK2i4svR.
PANC-1 cells endogenously express some CCK2R, while Panc02 cells can
express only the mouse isoform (but are, in fact, negative for mCCK2R RNA) and
thus serve as a negative control. Staining produced by anti-CCK2R (candidate
7B8.8) is shown; similar results were obtained using Abcam 77077 commercial
anti-CCK2R.

The next hypothesis tested was that the fixation protocol did not preserve membrane
structure. In particular, the pure acetone step in the original protocol (freezing in 100% methanol
followed by 100% acetone) was thought to destroy the membrane. Four alternative fixation
methods were tested in addition to the original protocol: 4% paraformaldehyde, 4%
paraformaldehyde followed by freezing in 100% methanol, freezing in a 1:1 acetone and
methanol mixture, and freezing in 100% methanol only. These fixation protocols were tested on
transiently-transfected 293FT-CCK2i4svR cells and stably-transfected PANC-1-CCK2i4svR cells.
Each was stained with 28H8 at 1:1000 and 1:5000. The new fixation protocols did not

significantly improve membrane preservation in 293FT-CCK2i4svR cells; several of the
conditions distorted membrane morphology more than the original protocol (Figure 9).
Additionally, no staining was visible in PANC-1-CCK2i4svR cells with any protocol (Figure 10).
The next hypothesis explaining the lack of detection was that the receptor may have low
stability or a low copy number per cell in the lines being tested. Previously, expression was
observed by immunofluorescence only in transiently-transfected 293FT cells. This derivative of
HEK293 cells contains the SV40 Large T-antigen, supporting a high episomal copy number of
the transfected plasmid and thus producing abnormally high levels of receptor expression. To
exclude the possibility that gradual loss/silencing of gene expression in the stable lines was
responsible for lack of detection, Panc02 cells were transiently transfected with CCK2R or
CCK2i4svR. However, no expression was detected in the transiently-transfected Panc02 cells
stained 24 or 48 hours post-transfection with 28H8, 7B8, 9A4, or 77077 at 1:100 or 1:1000
(Figure 11). The stock of 28H8 used in this experiment had been previously verified (40,000
titer). However, no 293FT cells were transfected in parallel as a positive control for transfection
efficiency.

Figure 9. Four new fixation methods gave similar results to the original protocol in
transiently-transfected 293FT cells. HEK293FT cells transiently transfected with CCK2i4svR
were stained with 28H8 at 1:5000 after fixation with five different protocols.

Figure 10. Four new fixation methods did not allow visualization of receptor expression in
stably-transfected PANC-1 cells. PANC-1 cells stably transfected with CCK2i4svR were stained
with 28H8 at 1:5000 after fixation with five different protocols.

A

B

Figure 11. No staining was visible in Panc02 cells transiently transfected with CCK2R or CCK2i4svR
at A) 24 or B) 48 hours post-transfection. No transfected cells were visible on any slides, as no cells
fluoresced more brightly than the background of non-transfected cells.

The final hypothesis explaining lack of receptor detection in stably-transfected or
parental cell lines was that the IF technique simply did not attain the necessary sensitivity to
detect the receptor at lower expression levels. Therefore, the antibodies next underwent
preliminary testing in an alternate application, IHC. Use of IHC should simultaneously have
increased sensitivity as an enzymatic method of detection and also allow testing of cells grown in
a more natural environment. Growth of cells in vivo rather than in vitro may lead to a more stable
expression and maintenance of the receptor. Nevertheless, in a preliminary IHC experiment, no
significant differences were seen between tumors grown from vector-only Panc02 cells and from
Panc02 cells stably transfected with CCK2R or CCK2i4svR (Figure 12).

Anti-CCK2i4svR
1:100

Anti-CCK2R
(Candidate 7B8.8)
1:100

Panc02
CCK2i4svR

Panc02
CCK2R

Panc02
Vector only

Secondary Only

Anti-CCK2i4svR
1:2000

Figure 12. No significant immunohistochemical staining of CCK2R- or CCK2i4svR-expressing
tumors was observed in a preliminary study. C57/BL6 mice were subcutaneously injected with
Panc02 cells expressing CCK2R or CCK2i4svR. Anti-CCKi4svR (28H8) and anti-CCK2R (candidate
7B8.8) were used to stain sections from these tumors. No significant staining was seen with either
antibody even though 28H8 had been verified in a previous study (Smith and Harms 2012).

DISCUSSION
Monoclonal antibodies are valuable tools for detecting the expression of proteins. The
ability to reliably detect CCK2R and CCK2i4svR expression will facilitate studies on the role of
these receptor forms in pancreatic cancer. This research demonstrated that previously-observed
differences in staining produced by two anti-CCK2R monoclonal antibody candidates (7B8.8
and 9A4.10) and an anti-CCK2i4svR antibody (28H8) when bound to the same receptor were not
due to differential localization of the antibodies. The anti-CCK2R and anti-CCK2i4svR antibodies
both colocalized with a commercial anti-CCK2R antibody, indicating that the previouslyobserved differential staining patterns were due to the limitation of only detecting the brightest
high-expressing cells with low titer antibody stocks. High titer stocks of the anti-CCK2R
antibodies allowed the visualization of membranous staining that was previously undetected.
Although there were no differences in antibody localization, anti-CCK2i4svR stained more
brightly than the two anti-CCK2R antibodies even when each was used at a similar titer,
potentially indicating that it has higher affinity for the receptor. This difference did not result
from the secondary antibody having higher affinity for one primary over the other, as 9A4.10,
7B8.8, and 28H8 are all of IgG1 antibody isotype with a kappa light chain. However, it could
potentially result from a difference in the location of the epitopes to which these antibodies bind.
Both 9A4.10 and 7B8.8 bind extracellularly, while 28H8 binds intracellularly. Therefore, it is
conceivable that 28H8 is more difficult to remove during washing steps, and therefore a greater
amount of antibody remains bound. This, and any potential difference in affinity, could be
addressed by modifying the stringency of wash steps.
The inability to detect receptor expression by IF in cells stably expressing the receptor at
lower, physiologically-relevant levels is currently a major hindrance to the use of the antibodies
in this application within our laboratory. It will be extremely important to verify the protocol

using 28H8 and Abcam 77077 commercial anti-CCK2R, as both of these antibodies have been
cited previously as effective in immunofluorescence. Further optimization of the IF procedure
may be necessary to improve detection. Use of alternate cell lines, or further verification of the
lines currently in use, will also be of importance. In particular, protein expression in any stablyor transiently-transfected Panc02 and PANC-1 lines used for IF analysis will need to be
confirmed. In one experiment presented in this paper, no receptor expression was detected in
transiently transfected Panc02 cells; however, this problem could potentially have resulted from
an inefficient transfection rather than from a defect in the IF procedure or the antibodies used. To
verify CCK2R expression in Panc02 cells, future research could include carrying out a Western
Blot on stably-transfected Panc02-CCK2R cells, conducting a transient transfection of Panc02
cells and simultaneously collecting samples for both IF and Western Blotting, or transfecting
Panc02 cells with a construct encoding a CCK2R-GFP fusion protein for analysis by IF.
Further characterization by IHC will also be beneficial in verifying the new anti-CCK2R
candidates. 28H8 has previously shown effectiveness in detecting CCK2i4svR by IHC (Smith et
al. 2012), so the protocol will need to be optimized to confirm this result. It may be necessary to
test mRNA or protein expression by qRT-PCR or Western Blotting in tumor samples flashfrozen in parallel with portions fixed and embedded for IHC. The use of additional tissue
samples may also allow for detection; in particular, human tumor samples which endogenously
express CCK2R may be more reliable than mouse Panc02 cells expressing human CCK2R.
Once the anti-CCK2R candidates have been demonstrated to detect the receptor at
physiological expression levels, they will be used in various applications to quantify receptor
expression in cell lines and patient samples. This will be of use to our laboratory and to
collaborators seeking to develop therapies targeting CCK2R.
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